Sichuan Hebang Biotechnology Stock Working Capital
| 603077 Stock | 2.04 0.01 0.49% |
Sichuan Hebang Biotechnology fundamentals help investors to digest information that contributes to Sichuan Hebang's financial success or failures. It also enables traders to predict the movement of Sichuan Stock. The fundamental analysis module provides a way to measure Sichuan Hebang's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sichuan Hebang stock.
The current year's Net Working Capital is expected to grow to about 6.5 B, whereas Change In Working Capital is projected to grow to (2.1 B). Sichuan | Working Capital |
Sichuan Hebang Biotechnology Company Working Capital Analysis
Sichuan Hebang's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Sichuan Hebang Working Capital | 6.18 B |
Most of Sichuan Hebang's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sichuan Hebang Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Sichuan Net Invested Capital
Net Invested Capital |
|
In accordance with the company's disclosures, Sichuan Hebang Biotechnology has a Working Capital of 6.18 B. This is much higher than that of the Chemicals sector and significantly higher than that of the Materials industry. The working capital for all China stocks is significantly lower than that of the firm.
Sichuan Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sichuan Hebang's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sichuan Hebang could also be used in its relative valuation, which is a method of valuing Sichuan Hebang by comparing valuation metrics of similar companies.Sichuan Hebang is currently under evaluation in working capital category among its peers.
Sichuan Fundamentals
| Return On Equity | 0.0231 | ||||
| Return On Asset | 0.0139 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | 18.89 B | ||||
| Shares Outstanding | 8.83 B | ||||
| Shares Owned By Insiders | 35.55 % | ||||
| Shares Owned By Institutions | 2.71 % | ||||
| Price To Book | 0.96 X | ||||
| Price To Sales | 1.96 X | ||||
| Revenue | 8.82 B | ||||
| Gross Profit | 5.55 B | ||||
| EBITDA | 1.61 B | ||||
| Net Income | 1.28 B | ||||
| Total Debt | 1.17 B | ||||
| Book Value Per Share | 2.34 X | ||||
| Cash Flow From Operations | 80.33 M | ||||
| Earnings Per Share | 0.06 X | ||||
| Target Price | 6.0 | ||||
| Number Of Employees | 7.17 K | ||||
| Beta | 0.33 | ||||
| Market Capitalization | 18.02 B | ||||
| Total Asset | 24.54 B | ||||
| Retained Earnings | 9.61 B | ||||
| Working Capital | 6.18 B | ||||
| Net Asset | 24.54 B |
About Sichuan Hebang Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sichuan Hebang Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sichuan Hebang using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sichuan Hebang Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Sichuan Stock
Sichuan Hebang financial ratios help investors to determine whether Sichuan Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sichuan with respect to the benefits of owning Sichuan Hebang security.